MX2022015524A - Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. - Google Patents

Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.

Info

Publication number
MX2022015524A
MX2022015524A MX2022015524A MX2022015524A MX2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A
Authority
MX
Mexico
Prior art keywords
crystalline forms
ureido
propoxy
trans
acetic acid
Prior art date
Application number
MX2022015524A
Other languages
English (en)
Spanish (es)
Inventor
Jing Teng
Yizheng Cao
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2022015524A publication Critical patent/MX2022015524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2022015524A 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. MX2022015524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015524A true MX2022015524A (es) 2023-03-22

Family

ID=78846441

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022015524A MX2022015524A (es) 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
MX2026000786A MX2026000786A (es) 2020-06-08 2022-12-06 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4- propoxiciclohexil)-ureido]-thiazol-5-ilsulfanil}acetico y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2026000786A MX2026000786A (es) 2020-06-08 2022-12-06 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4- propoxiciclohexil)-ureido]-thiazol-5-ilsulfanil}acetico y usos de las mismas

Country Status (9)

Country Link
US (1) US20230219910A1 (https=)
EP (1) EP4161639A4 (https=)
JP (1) JP2023530785A (https=)
KR (1) KR20230048501A (https=)
CN (2) CN121202809A (https=)
AU (1) AU2021289591A1 (https=)
CA (1) CA3181665A1 (https=)
MX (2) MX2022015524A (https=)
WO (1) WO2021252309A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
NZ603614A (en) * 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
BR112014028622A2 (pt) * 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CN105050585A (zh) * 2013-03-04 2015-11-11 Vtv治疗有限责任公司 稳定的葡萄糖激酶活化剂组合物
EP3556354B1 (en) * 2016-12-15 2025-05-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor

Also Published As

Publication number Publication date
JP2023530785A (ja) 2023-07-19
US20230219910A1 (en) 2023-07-13
CN121202809A (zh) 2025-12-26
KR20230048501A (ko) 2023-04-11
CA3181665A1 (en) 2021-12-16
EP4161639A4 (en) 2024-01-17
AU2021289591A1 (en) 2023-01-19
EP4161639A1 (en) 2023-04-12
WO2021252309A1 (en) 2021-12-16
MX2026000786A (es) 2026-03-02
CN116056760A (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
CL2021002963A1 (es) Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
BRPI0409109A (pt) novos compostos
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
UY38986A (es) Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
AR032752A1 (es) Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
HRP20180113T1 (hr) Uporaba metformina u kombinaciji s aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze
DOP2025000146A (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
CO2023008949A2 (es) Forma cristalina de tolebrutinib, método de preparación y uso de la misma
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
RU2011117927A (ru) Карбаматное соединение или его соль
SE8400332D0 (sv) Forening for anvendning som mellanprodukt vid framstellning av lekemedel
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
ES2038630T3 (es) Un procedimiento para preparar un compuesto de acido fenoxiacetico.
ES2046193T3 (es) Un procedimiento para la preparacion de un compuesto de imidazolidinona.
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
MX9307257A (es) Dimetilbenzofuranos y dimetilbenzopiranos como antagonistas de 5-ht3.
AR071255A1 (es) Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados